[ATRA] Atara Biotherapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 622.51 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.65 Change: 1.15 (7.93%)
Ext. hours: Change: 0 (0%)

chart ATRA

Refresh chart

Strongest Trends Summary For ATRA

ATRA is in the medium-term down -31% in 1 month and down -53% below S&P in 6 months. In the long-term up 63% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.

Fundamental Ratios
Shares Outstanding28.74 M EPS-3.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.18
P/E To EPS Growth P/S P/BV3.75 Price/Cash Per Share3.73
Price/Free Cash Flow-37.33 ROA-17.74% ROE-18.13% ROI
Current Ratio48.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities69.49 M Cash From Investing Activities-13.43 M Cash From Operating Activities-6.62 M Gross Profit
Net Profit-9.16 M Operating Profit-9.31 M Total Assets169.82 M Total Current Assets169.69 M
Total Current Liabilities3.51 M Total Debt Total Liabilities3.72 M Total Revenue
Technical Data
High 52 week46.05 Low 52 week23.99 Last close23.99 Last change-0.74%
RSI24.66 Average true range2.16 Beta1.91 Volume116.19 K
Simple moving average 20 days-21.91% Simple moving average 50 days-31.48% Simple moving average 200 days-35.01%
Performance Data
Performance Week-7.73% Performance Month-26.37% Performance Quart-40.69% Performance Half-30.98%
Performance Year-45.66% Performance Year-to-date-30.94% Volatility daily5.98% Volatility weekly13.37%
Volatility monthly27.4% Volatility yearly94.93% Relative Volume166.51% Average Volume589.17 K
New High New Low

News

2019-06-25 16:05:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-23 15:52:49 | Were Hedge Funds Right About Flocking Into Atara Biotherapeutics Inc ATRA ?

2019-06-05 16:30:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635C4

2019-06-04 09:36:00 | Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

2019-06-03 11:00:00 | Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO

2019-06-01 09:00:00 | Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology ASCO Annual Meeting

2019-05-30 17:38:16 | Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

2019-05-28 17:00:00 | Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors

2019-05-15 17:05:00 | Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology ASCO Annual Meeting

2019-05-15 08:30:00 | Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology EAN

2019-05-10 09:29:57 | Edited Transcript of ATRA earnings conference call or presentation 9-May-19 12:30pm GMT

2019-05-09 15:25:00 | Why Atara Biotherapeutics Stock Is Imploding Today

2019-05-09 08:19:32 | Atara Biotherapeutics: 1Q Earnings Snapshot

2019-05-09 08:00:00 | Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress

2019-05-09 06:30:00 | Atara Biotherapeutics, Inc. to Host Earnings Call

2019-05-07 16:41:24 | Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019

2019-05-07 09:00:00 | Where Will Gilead Sciences Spend Its Cash?

2019-05-02 12:42:54 | Here is What Hedge Funds Think About Atara Biotherapeutics Inc ATRA

2019-04-23 08:44:00 | 2 Best Biotech Buyout Plays

2019-04-01 16:10:00 | Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research AACR Annual Meeting 2019

2019-03-31 11:00:00 | Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

2019-03-08 13:55:07 | The Atara Biotherapeutics NASDAQ:ATRA Share Price Has Gained 122%, So Why Not Pay It Some Attention?

2019-03-07 09:00:00 | Atara Biotherapeutics to Participate in Upcoming Conferences

2019-03-06 17:20:40 | How attacking a virus in cancer patients helped a Peninsula company target MS

2019-02-27 17:20:00 | Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research AACR Annual Meeting 2019

2019-02-26 07:30:00 | Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress

2019-02-13 08:00:00 | Consolidated Research: 2019 Summary Expectations for T-Mobile US, WestRock, Shake Shack, Atara Biotherapeutics, CorVel, and Transdigm Group — Fundamental Analysis, Key Performance Indications

2019-01-08 12:50:13 | At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

2019-01-04 16:05:00 | Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference

2019-01-04 10:01:03 | Company News For Jan 4, 2019

2019-01-03 16:32:00 | Why Delta Air Lines, Atara Biotherapeutics, and Skyworks Solutions Slumped Today

2019-01-03 07:40:00 | Atara Biotherapeutics Announces Planned Chief Executive Officer Transition

2019-01-03 07:30:00 | Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors

2018-12-21 23:23:46 | Should You Avoid Atara Biotherapeutics Inc ATRA?

2018-12-15 08:00:00 | Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma EBV+ LMS

2018-12-03 20:45:00 | Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology ASH Annual Meeting

2018-11-29 14:50:00 | Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline

2018-11-27 08:30:00 | Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018

2018-11-19 08:30:00 | Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus EBV-Specific T-Cell Immunotherapy

2018-11-06 08:11:19 | Atara Biotherapeutics: 3Q Earnings Snapshot

2018-11-06 07:30:00 | Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress

2018-11-01 09:03:00 | Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology ASH Annual Meeting and European Society for Medical

2018-10-16 07:40:00 | Report: Exploring Fundamental Drivers Behind Monroe Capital, Anavex Life Sciences, Haynes International, Atara Biotherapeutics, Lands' End, and Envestnet — New Horizons, Emerging Trends, and Upcoming Developments

2018-09-26 08:41:12 | Atara Biotherapeutics ATRA in Focus: Stock Moves 6.9% Higher

2018-09-24 16:55:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-09-11 08:00:00 | Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors

2018-09-06 07:30:00 | Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies

2018-08-31 08:00:00 | Atara Biotherapeutics to Participate at Two Upcoming Conferences

2018-08-16 07:40:00 | Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, and Consolidated Results

2018-08-06 16:50:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4